Treating Addiction as a Chronic Disease

Similar documents
Mass General s Substance Use Disorder Initiative

Opioid Use Disorder Treatment Initiation in Diverse Settings

The MGH Substance Use Disorder Initiative Sarah E. Wakeman, MD, FASAM Medical Director Assistant Professor of Medicine, Harvard Medical School

The Chronic Disease of Addiction Evidence and Lessons from Practice

Can 12 Step and Medications for Substance Use Disorders Co-Exist?

Treatment Approaches for Drug Addiction

Infectious Disease and the Opioid Epidemic: Correctional Health

MGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT

THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.

Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.

Treatment Team Approaches in Substance Abuse Treatment

MGH Inpatient Addictions Consult Team Management of Opioid Use Disorder

NIDA Principles of Treatment. NIDA Principles of Treatment. Peter Banys, M.D., M.Sc. No single treatment is appropriate for all individuals.

Pennsylvania Coordinated Medication Assisted Treatment: A Penn State and Pennsylvania Psychiatric Institute Story

Care in the Face of the Opioid Epidemic: How Yale University and Yale New Haven Hospital are Reaching Underserved Communities

Treatment Alternatives for Substance Use Disorders

THE STATE OF MEDICINE IN ADDICTION RECOVERY

Wasted AN INTRODUCTION TO SUBSTANCE ABUSE

Medical Interventions for Addiction in Primary Care Settings. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale University School of Medicine

Mark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC

The opioid crisis: A view from NIDA

Hospitals Role in Addressing the Opioid Crisis

Medication for the Treatment of Addiction (MAT)

Mental Health and Behavioral Health

Health Systems and Addiction: Provider Issues

Medication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs

RECOMMENDATIONS FOR HEALTH CARE PROVIDERS

The Importance of Psychological Treatment and Behavioral Support

The Opioid Crisis: What Can Physicians Do About It?

The Science of Drug Addiction: Implications for Clinical Practice

Stigma, Myths, Realities Limit Access to Care

An Internist s Guide to Unhealthy Alcohol Use. Ryan Graddy, MD JHU SOM

PHARMACOTHERAPY OF SMOKING CESSATION

Opioids and Opioid Addiction: Practical Management Approaches

Serious Mental Illness and Opioid Use Disorder

Noel Schenk MD. Davis Behavioral Health

Best Practice Workgroup Considerations. New Jersey Shared Values: Unified Child Welfare Practice Conference April 29, 2011

Page 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk

Pharmacologic Interventions for. Addictions

9/17/2018 MISSION IMPOSSIBLE: IF YOU CHOOSE TO ACCEPT MISSION JOIN JUSTICE LEAGUE I M POSSIBLE HEPBURN

5/30/ New England Summer School Lindy S. Keller, M.S., MLADC - NH Bureau of Drug & Alcohol Services. Objectives

Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center

ADDICTION CHANGING OUR ASPECT OF PRACTICE. Natasha N. Bray, DO, MSEd Visiting Clinical Associate Professor of Rural Medicine Internal Medicine

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

BASIC VOLUME. Elements of Drug Dependence Treatment

Medication Assisted Treatment of Substance Use Disorders

Opioid Use and Justice Involvement: Challenges in Treatment, Engagement, and Continuity

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Substance Use Disorders in Primary Care

Complex Mental Illness and Concurrent Addictions

Buprenorphine as a Treatment Option for Opioid Use Disorder

V. EVIDENCE-BASED APPROACHES TO TREATING ADOLESCENT SUBSTANCE USE DISORDERS

Treating Addiction as a Chronic Illness: Why it is Finally Possible. A. Thomas McLellan Treatment Research Institute

Addiction Medicine: What s new for primary care

Opioid Use Disorder Treatment: Buprenorphine Treatment Basics

POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE

Dr. Renner receives honoraria from Reed Medical Education

Medication for Addiction Treatment (MAT)

The Science of Drug Addiction: Implications for Clinical Practice

Heroin, Fentanyl and Other Opioids. Steve Hanson

Pharmacotherapy for opioid addiction. Judith Martin, MD Medical Director BAART Turk Street Clinic San Francisco

Substance Abuse. Heather Gotham, PhD, Licensed Clinical Psychologist September 9, TB Nurse Case Management September 7-9, 2016 San Antonio, TX

Division of Mental Health and Addiction Services

Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry

Treatment of Substance Use Disorders in the Real World. Jessica M. Peirce, Ph.D. Johns Hopkins University School of Medicine

Methadone and Naltrexone ER

Medical Management of Substance Use Disorders: Does research translate to clinical practice

The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016

Medications in the Treatment of Opioid Use Disorder: Methadone and Buprenorphine What Really Are They?

An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT

Opioids Research to Practice

MEDICATION-ASSISTED TREATMENT FOR OPIOID USE DISORDER

Opioid Use Disorders &Medication Treatment

Extended-Release Naltrexone for Opioid Relapse Prevention Among Community Criminal Justice Participants

Arwen Podesta, MD. ABIHM, ABAM, Forensic Psychiatry

Initiation and engagement in addiction treatment integrated into primary care: the role of gender

Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction

Opioid Withdrawal, Opioid Substitution, and HIV Infection

AODA RECOVERY. How to support those in recovery, and those not yet ready to commit

Opioid Dependence 101 and Medication Assisted Treatment

6/27/2017. Disclosures. Overview. Case Overview

8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy

Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates

ADDICTION ELEMENTS OF ADDICTION. Medication Assisted Treatment of Substance Use Disorders Ron Jackson, MSW, LICSW. Substance Use Disorder DSM 5

Pharmacotherapy of Alcohol Use Disorders

Opioids Research to Practice

Making Referrals. Welcome to the Recovery U module on making referrals.

Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations

7/7/2016 Journal of the American Medical Association,

Restoration of Parenting Ability Through Treatment for Substance Use Disorders

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Integrated Treatment of Co-morbid

Introduction to pharmacotherapy

Evidence Based Clinical Practice Guidelines for the Management of Persons with Substance Use Disorders Daniel Kivlahan, PhD

Building capacity for a CHC response to Ontario's Opioid Crisis

Addictions 101: Understanding, Recognizing, and Treating the Disease State!

Opioid Overdose: Risks, Clinical Features, Treatment, and Reduction of Negative Consequences

LESSONS FROM THE PHYSICIAN HEALTH PROGRAM (PHP) EXPERIENCE FOR TODAY'S NATIONAL OPIOID EPIDEMIC

Primer on Opioid Use Disorders A Brain Disease

4/5/2018 MEDICATION ASSISTED TREATMENT FOR OPIOID USE DISORDERS OBJECTIVES DEFINITION OF ADDICTION APRIL 11, 2018 RITU BHATNAGAR, M.D., M.P.H.

Transcription:

Treating Addiction as a Chronic Disease Sarah E. Wakeman, MD, FASAM Medical Director, MGH Substance Use Disorder Initiative Assistant Professor of Medicine, Harvard Medical School

Disclosures Neither I nor my spouse/partner has a relevant financial relationship with a commercial interest to disclose.

Addiction The question is frequently asked: Why does a man become a drug addict? The answer is that he usually does not intend to. Junk wins by default. I tried it as a matter of curiosity. I drifted along taking shots when I could score. I ended up hooked. You don t decide to be an addict. One morning you wake up sick and you re an addict. William S. Burroughs, Junky (1953)

Natural History of Opioid Use Disorder Using to feel good Needing to use more to feel normal Using to keep from getting sick

A Disease of Gene Environment Development Onset depends on many intrinsic and extrinsic factors Biology Genes/Development Environment DRUG/ALCOHOL Brain Mechanisms Addiction Slide courtesy of Dr. Compton, NIDA

Defining Addiction Primary, chronic brain disease characterized by compulsive drug seeking and use despite harmful consequences Involves cycles of relapse and remission 40 60% genetic Without treatment addiction is progressive and can result in disability or premature death American Society of Addiction Medicine. April 12, 2011. www.asam.org NIDA. August, 2010. http://www.drugabuse.gov/publications/science addiction

Defining Chronic Illness Long in duration often with protracted clinical course Associated with persistent and recurring health problems Multi factorial in etiology, often heritable No definite cure Requires ongoing medical care Goodman RA, et al. Prev Chronic Dis 2013;10:120239. Martic CM. Can Fam Physician. 2007 Dec; 53(12): 2086 2091.

SUD Meets Criteria for Chronic Illness Common features with other chronic illnesses: Heritability Influenced by environment and behavior Responds to appropriate treatment Without adequate treatment can be progressive and result in substantial morbidity & mortality Has a biological/physiological basis, is ongoing and long term, can involve recurrences https://archives.drugabuse.gov/about/welcome/aboutdrugabuse/chronicdisease/de long term lifestyle modification http://www.asam.org/quality practice/definition of addiction

Addiction Changes Brain Structure and Function Decreased Heart Metabolism in Coronary Artery Disease High Decreased Brain Metabolism in Addiction Healthy heart Diseased Heart Low Healthy Brain Diseased Brain NIDA

A Treatable Disease NIDA. Principles of Drug Addiction Treatment. 2012. McLellan et al., JAMA, 284:1689 1695, 2000.

Relapse & Chronic Disease NIDA. Principles of Drug Addiction Treatment. 2012. McLellan et al., JAMA, 284:1689 1695, 2000.

Visualizing Recovery Volkow et al. J. Neurosci., December 1, 2001, 21(23):9414 9418

Cost Savings of Treatment SAMHSA, 2009.

What is Effective Treatment? NIDA, 2012 https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/podat_1.pdf

What is Effective Treatment? Pharmacotherapy Alcohol use disorder naltrexone, acamprosate, disulfiram, topiramate* Opioid use disorder methadone, buprenorphine, naltrexone Tobacco use disorder varenicline, bupropion, NRT Cocaine use disorder Topiramate*, naltrexone* Psychosocial/behavioral Levels of care Outpatient, IOP/PHP, residential Modalities CBT, MI/MET, CM, TSF Recovery Supports Mutual help/peer support Recovery coaching * not FDA approved but some research suggesting modest efficacy

Similar to Medical Management ofother Chronic Illnesses (e.g. Diabetes or HIV) No cure Goal is prevention of acute and chronic complications Individualized treatment plans and targets Treatment includes: Medication Lifestyle changes Regular monitoring for complications Behavioral support 16

Learning from HIV/AIDS

Medication Saves Lives

Medication Saves Lives Perinatal mortality in type 1 diabetic mothers, Belfast, 1940 1990. The control group is the total perinatal mortality for all pregnancies managed at the same hospital.

Medication Saves Lives Maryland: 50% reduction in overdose death with opioid agonist treatment France: 79% reduction in overdose death opioid agonist treatment

Long term Outcomes: Most Patients in Remission Weiss et al. Drug Alc Depend. 2015;150:112 9.

How Long Should Treatment Last? In most cases, treatment will be required in the long term or even throughout life. The aim of treatment services is not only to reduce or stop opioid use, but also to improve health and social functioning, and to help patients avoid some of the more serious consequences of drug use. Such long term treatment, common for many medical conditions, should not be seen as treatment failure, but rather as a cost effective way of prolonging life and improving quality of life, supporting the natural and long term process of change and recovery. World Health Organization http://apps.who.int/iris/bitstream/10665/4 3948/1/9789241547543_eng.pdf

Enabling Health I got into harm reduction to enable people who use drugs. I enable them to protect themselves and their communities from HIV and hepatitis C and overdose. I enable them to feel like they have someone to talk to, someone who cares, someone who respects them and their humanity. If that makes me an enabler, I m proud to claim that term. Daniel Raymond, Director of Policy, Harm Reduction Coalition. 23

Thank you! @DrSarahWakeman swakeman@partners.org